Physician profile
Krishna Gundabolu
NPI 1710250899
$75,945.27
in general payments reported to CMS, 2019-2025
21 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $16K · 2021: $4,466 · 2022: $19K · 2023: $4,717 · 2024: $1,694 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,126 · Travel and Lodging: $1,915 · Food and Beverage: $1,483 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,226.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,126.42 |
| Travel and Lodging | $1,915.45 |
| Food and Beverage | $1,482.78 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14,216.00 | 2020-2023 | |
| Biomarin Pharmaceutical INC. | $10,648.66 | 2019-2020 | |
| Incyte Corporation | $7,837.09 | 2025 | Niktimvo |
| Blueprint Medicines Corporation | $7,076.85 | 2020-2022 | |
| Spark Therapeutics, INC. | $6,221.72 | 2022 | |
| Jazz Pharmaceuticals INC. | $5,603.96 | 2019 | |
| Sobi, INC | $5,511.38 | 2025 | |
| Syndax Pharmaceuticals, INC. | $4,770.93 | 2025 | Revuforj |
| Novartis Pharmaceuticals Corporation | $4,021.13 | 2020-2023 | Fabhalta |
| Genzyme Corporation | $2,996.00 | 2022 | |
| Pfizer INC. | $2,152.45 | 2019-2024 | |
| Cti Biopharma Corp. | $1,725.00 | 2022 | |
| Abbvie INC. | $1,349.22 | 2024-2025 | |
| National Marrow Donor Program | $974.20 | 2024 | |
| Celgene Corporation | $574.24 | 2023-2025 | Reblozyl, Pomalyst |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $177.45 | 2021 | |
| Astellas Pharma US INC | $88.99 | 2021-2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Gundabolu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.